I am a clinician-scientist in infectious and tropical diseases, working towards the better understanding of the pathophysiology of malaria and other tropical diseases of public health importance in our region, and new ways of prevention and treatment.
Intensive Care patients more often than not, develop kidney failure requiring dialysis. Unfortunately there is little information available to inform clinicians of appropriate doses for antibiotics in these patients, putting them at an increased risk of death from ineffective treatment. Our project aims to develop dosing guidelines for the many types of dialysis used globally to achieve concentrations in the blood that optimise antibiotic effects in these most critically ill patients.
Improving Outcomes In Patients With Community-acquired Severe Sepsis: The Role Of Pre-hospital Antibiotics.
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
Severe sepsis occurs when infection causes organ dysfunction. If not treated early, outcomes remain poor. Foremost in effectively treating this condition is the initiation of broad-spectrum antibiotics. This Fellowship will assess the feasibility, efficacy, and safety of pre-hospital antibiotics administered by paramedics to patients with suspected community-acquired severe-sepsis, as a means to improve patient outcomes in this highly vulnerable group.
Establishing The Capacity For H5N1 Challenge Of Ferrets Within Australia &optimizing Pandemic Vaccines In This Model
Funder
National Health and Medical Research Council
Funding Amount
$405,513.00
Summary
Australia is currently in the process of manufacturing vaccines for use in people against strains of avian influenza viruses circulating in South East Asia as part of a national preparedness program for an influenza pandemic. These particular avian flu viruses are capable of causing severe disease and death in humans as well as birds, although at present they are not highly transmissible between people. Should the avian influenza viruses mutate to gain this capability, it will be necessary to in ....Australia is currently in the process of manufacturing vaccines for use in people against strains of avian influenza viruses circulating in South East Asia as part of a national preparedness program for an influenza pandemic. These particular avian flu viruses are capable of causing severe disease and death in humans as well as birds, although at present they are not highly transmissible between people. Should the avian influenza viruses mutate to gain this capability, it will be necessary to institute widespread vaccination of the Australian population. It is not possible to test the vaccines in people for their effectiveness against avian influenza infection prior to a disease outbreak, so an animal model for the disease will be used to assist in optimizing the formulation of flu vaccines and in testing their efficacy in preventing infection or reducing the severity of disease. Ferrets are natural hosts for flu viruses, have similar responses to vaccination as people, and develop a similar disease to humans when infected with influenza. These animals will be used to assist vaccine manufacturers in providing the best type of vaccine for protection of Australians in the face of a global flu pandemic.Read moreRead less
Economic, social and cross cultural issues in non-pharmaceutical protection of front line responders to pandemic influenza and emerging infections. The protection of front line responders in a pandemic is essential to underpin an effective response. This research is the only work internationally which will address a key gap in evidence. This research has major implications for the national stockpile and for management of front line responders in a pandemic. These data are urgently needed, not ju ....Economic, social and cross cultural issues in non-pharmaceutical protection of front line responders to pandemic influenza and emerging infections. The protection of front line responders in a pandemic is essential to underpin an effective response. This research is the only work internationally which will address a key gap in evidence. This research has major implications for the national stockpile and for management of front line responders in a pandemic. These data are urgently needed, not just in Australia, but globally to inform pandemic planning and disease control policy around emerging infections and bioterrorism.Read moreRead less
Malaria And Infectious Diseases In The Asia-Pacific: Drugs, Vaccines And Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$210,873.00
Summary
Dr Karunajeewa is an expert in the treatment of malaria and other infectious diseases that have a major impact on the health of people living in developing countries of the tropical zone of the Asia-Pacific region. His ongoing research aims to develop better ways of diagnosing these infections, defining their relative importance in terms of overall burden of disease, finding optimal drug treatments and testing the effectiveness of new vaccines for their prevention.
Rapid Prediction Of Antibiotic Resistance In The Enterobacteriaceae: Making Use Of Restricted Diversity In Mobile Resistance Gene Pools
Funder
National Health and Medical Research Council
Funding Amount
$385,032.00
Summary
Immediate treatment of patients suffering life-threatening bacterial infections with effective antibiotics greatly improves their chances of survival, but antibiotic resistance increasingly complicates this treatment. Currently such resistance cannot be detected in time to help decide the best antibiotic to use. We aim to define a small set of the many known antibiotic resistance genes that can be used accurately predict resistance in rapid tests using modern detection systems.
Mathematical modelling can provide vital information on the effectiveness and practical implementation of microbicides and vaccines against HIV. This project will produce mathematical models of the earliest stages of HIV infection suitable for investigation of the implementation of vaccines and microbicides. It will provide a framework to investigate why these interventions have performed poorly to date, and how these may be better implemented.
RV3 Rotavirus Vaccine: Developing A Neonatal Rotavirus Vaccine Formulation For The Global Community
Funder
National Health and Medical Research Council
Funding Amount
$135,075.00
Summary
Rotavirus infection is the leading cause of severe dehydrating gastroenteritis responsible for approximately 600,000 deaths per year in children under 5 years of age worldwide. There is a commercial and public health opportunity to develop a new rotavirus vaccine that can be given at birth. By modifying the way the vaccine is made we hope that it will be more acceptable and easily delivered to children in remote communities and developing countries without the need for refrigeration.